PitchSend

Nuvectis Pharma Investor Presentation Deck

NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family Differentiated vs. other multi-kinase inhibitors that only achieve a partial SRC pathway shut down NXP900: Complete shutdown of the SRC pathway SH3 SH2 P pY530 NuvectisPharma, Inc. NON- FUNCTIONAL scaffolding site C-helix E313 NXP900 Y419 Kinase Closed, inactive conformation locked by NXP900 NXP900 Oncogenic signal No inhibitor: Fully active SRC Y530 SH3 SH2 C-helix E313 Fully functional scaffolding site - Binding to YAP, FAK, CAS, paxillin pY419 Kinase Open, active conformation no inhibitor Other multi-kinase inhibitors Other multi-kinase inhibitors: Partial shutdown of the SRC pathway } Y530 SH3 SH2 C-helix E313 Fully functional scaffolding site - Binding to YAP, FAK, CAS, paxillin Kinase Other multi-kinase inhibitors Y419 Open, active conformation stabilized by other multi-kinase inhibitors 16

View entire presentation